CION Ameerpet
Glioblastoma almost always recurs, even after the best first treatment — that is the tumour's biology, not a failure of your care. There are still meaningful options, and our tumour board weighs every one with you.
Being told your glioblastoma (GBM) has returned is one of the hardest moments in the whole journey. It can feel like the first treatment did not work. It is important to hear this clearly: glioblastoma recurs in almost everyone, even after the best possible surgery, radiation and chemotherapy. Recurrence is an expected stage of GBM — it reflects the biology of the tumour, not a failure of you or your care team.
And it is not the end of the road. There is no single fixed protocol for recurrent GBM, which means the plan is personalised to you — your previous treatment, how long the tumour stayed controlled, your fitness, where it has come back, and your molecular markers all shape what is possible. The most useful next step is to have your full records reviewed together by a brain tumour team, so every option is weighed at once rather than one at a time. Our team can also guide you through treating a recurrent brain tumour more broadly.
Because no single therapy is clearly best for recurrent glioblastoma, both NCCN (National Comprehensive Cancer Network) and EANO (European Association of Neuro-Oncology) guidelines list enrolment in a clinical trial as an appropriate — and sometimes preferred — option at recurrence. A trial is not a last resort; it is a structured, carefully monitored way to access newer approaches.
Before changing your treatment, your team needs to be sure the scan is showing true tumour growth and not a treatment effect. After chemoradiation, an MRI can look worse because of inflammation rather than real recurrence — a phenomenon called pseudoprogression. It usually appears within the first few months after radiation, and mistaking it for recurrence can lead to stopping a treatment that is actually working.
To tell them apart, CION delivers advanced MRI assessment directly — perfusion MRI and MR spectroscopy — alongside short-interval repeat imaging. Where the picture is still unclear, a biopsy can be arranged, coordinated with our accredited neurosurgical partners, to confirm the diagnosis and provide fresh tissue for molecular testing. Getting this interpretation right is one of the strongest reasons to seek a specialist review before committing to any next step.
Worried your scan has changed? Ask our neuro-oncology team to review your MRI — a written second opinion is free.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether your GBM has just come back or you want a second opinion before the next decision, CION's neuro-oncology tumour board will weigh every option with you — across our Hyderabad centres.
There is no single standard for recurrent GBM — that is exactly why a personalised plan matters. The options below are considered alone or in combination, guided by NCCN and EANO recommendations and decided together at our tumour board.
For an accessible recurrence in a patient who is fit, repeat surgery can reduce tumour bulk, relieve pressure, confirm true tumour, and yield fresh tissue for molecular testing. CION has no in-house neurosurgeon — any operation is coordinated with our accredited neurosurgical partners, while we manage the imaging, molecular testing, radiation and systemic therapy around it.
When the recurrence is relatively small and enough time has passed since the first course, focused stereotactic radiosurgery can re-treat the area while limiting dose to healthy brain. Delivered as part of coordinated radiosurgery and specialist care, CION's radiation oncology team plans these treatments using detailed MRI-based targeting.
This class of drug targets the tumour's blood-vessel growth. In recurrent GBM it is mainly used to control swelling (oedema) and ease symptoms, often reducing the need for high-dose steroids. We describe therapy by mechanism and discuss realistic benefits and side effects honestly with you.
In selected patients — particularly those whose tumour responded well and stayed controlled for a long time, and whose MGMT marker is favourable — a rechallenge with alkylating chemotherapy may be an option. The decision weighs prior response, fitness and blood counts.
An approach that uses low-intensity electric fields to interfere with tumour cell division, worn as a wearable device. CION discusses and arranges this as part of coordinated specialist care where appropriate, rather than as an in-house device.
Because no therapy is clearly best at recurrence, a clinical trial is a reasonable — sometimes preferred — first choice under NCCN and EANO. Trials may open access to new drug classes, novel radiation, or immunotherapy strategies. We review your records and coordinate referral where you may be eligible.
At recurrence, the same scan can lead to different recommendations for different people. Our tumour board weighs several factors together before advising a path:
Telling true recurrence apart from pseudoprogression can change the entire plan. Pseudoprogression — inflammation that mimics tumour growth on MRI — typically appears within the first few months after chemoradiation. Advanced MRI (perfusion and spectroscopy) and short-interval repeat scans help experienced neuro-oncologists avoid stopping a working treatment too early.
Families often ask what recurrence means for the time ahead. We answer honestly, but with care. Outcomes after glioblastoma recurrence vary widely and depend on factors such as how long the tumour stayed controlled, your fitness, MGMT status, and which treatments remain available.
Published series describe a range of survival after recurrence rather than a single number, and individuals can differ greatly from any average — some people do considerably better than the figures suggest. We will never give you a guarantee or a frightening countdown. Instead we share individualised information, framed in the context of your own situation, so you and your family can make decisions that feel right.
Just as important: quality of life and symptom control are part of the plan from day one. Learn more about glioblastoma or explore brain tumour treatment in Hyderabad to see how we coordinate the full pathway.
Recurrent GBM care is about how you feel and function, not only the scan. Alongside any anti-tumour treatment, CION delivers a full layer of supportive care directly:
Decisions for healing, not billing. We explain transparent costs up front, and we walk this journey with you. Call 18002028726 or book a free consultation to talk through your options today.
Get a free written second opinion from CION's neuro-oncology tumour board — especially valuable before deciding on re-surgery, re-irradiation, or whether a clinical trial fits your situation.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.No. Glioblastoma (GBM) recurs in almost everyone, even after the best possible surgery, radiation and temozolomide chemotherapy. This is the biology of the tumour, not a failure of your first treatment or your care team. Recurrence is an expected stage of the GBM journey — and there are real, meaningful options at this point. The right next step depends on where the tumour has come back, how much time has passed since your last treatment, your fitness, and your molecular markers. The most useful thing you can do now is get your full records reviewed together by a brain tumour team so every option is weighed at once.
There is no single standard for recurrent glioblastoma — the plan is personalised. Options that may be considered, alone or in combination, include: repeat surgery (coordinated with neurosurgical partners) to remove accessible tumour and relieve pressure; re-irradiation, often focused stereotactic radiosurgery, when the recurrence is small and enough time has passed; anti-angiogenic therapy, which can ease swelling and symptoms; alkylating chemotherapy rechallenge in selected patients; tumour treating fields as part of coordinated specialist care; and clinical trials. NCCN and EANO both emphasise that a clinical trial is a reasonable first choice at recurrence. A recurrent brain tumour review matches you to the options that fit your situation.
Sometimes — it depends on where the tumour has returned, your overall fitness, and how much functional brain is at risk. Repeat surgery can reduce tumour bulk, relieve pressure, confirm that the change on the scan is true tumour rather than treatment effect, and provide fresh tissue for molecular testing. CION does not have an in-house neurosurgeon, so any operation — including stereotactic biopsy or repeat resection — is coordinated with our accredited neurosurgical partners, with CION managing the imaging, molecular testing, radiation and systemic therapy around it. The tumour board decides together whether surgery adds enough benefit to justify the risks.
After chemoradiation, a scan can look worse because of treatment-related inflammation rather than real tumour growth — this is called pseudoprogression, and it usually appears within the first few months. Mistaking it for recurrence can lead to stopping a working treatment too early. To tell them apart, our team uses advanced MRI sequences (perfusion and spectroscopy), short-interval repeat imaging, and sometimes a biopsy coordinated with our neurosurgical partners. Experienced neuro-oncologists recognise this pattern and avoid changing the plan prematurely. Getting the interpretation right is one of the most important reasons to seek a specialist review.
Often, yes. Because no single therapy is clearly best for recurrent GBM, both NCCN and EANO guidelines list clinical trial enrolment as an appropriate option at recurrence — sometimes a preferred one. Trials may offer access to new drug classes, novel radiation approaches, or immunotherapy strategies not yet routinely available. CION can review your records, explain which trial categories you might be eligible for, and coordinate referral where appropriate. Trials are not a last resort or an experiment done on you — they are a carefully monitored, structured option, and many patients value having every door explored. Ask our team what may be open to you.
Outcomes after recurrence vary widely and depend on factors such as how long your tumour stayed controlled, your fitness, MGMT methylation status, and which treatments remain available. Published series describe a range of survival after recurrence rather than a single number, and individuals can differ greatly from any average. We share honest, individualised information — never guarantees — and we frame it gently, because numbers are only part of the picture. Quality of life, symptom control, and your own goals matter just as much. Our team will sit with you and your family to plan care around what matters most to you.
A great deal. Recurrent GBM care is not only about shrinking the tumour — it is about how you feel and function. CION delivers steroid management to control brain swelling, seizure (antiepileptic) management, and supportive and rehabilitative care including physiotherapy, speech and cognitive support. We coordinate palliative care early — not as giving up, but as adding a layer of comfort and symptom control alongside active treatment. Your family is part of every conversation. We walk this journey with you, with transparent costs and a 45-minute consultation so nothing feels rushed.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.